“Tasquinimod prolonged survival in men with minimally symptomatic, metastatic castration-resistant prostate cancer compared with placebo, according to results of a randomized, phase 2 study. Results suggest the survival advantage was particularly apparent among men with skeletal metastases. The study included 201 men. Researchers assigned 134 of them to tasquinimod (Active Biotech), an oral immunomodulatory, anti-angiogenic and anti-metastatic novel agent. The other 67 men were assigned placebo; however, 41 of them crossed over to treatment with tasquinimod during the study.”
- skeletal-related events
“An updated analysis of the results of a phase III clinical trial showed that radium-223 dichloride (Xofigo) significantly improved overall survival (OS) and delayed time to the first skeletal-related event (SRE) in patients with metastatic prostate cancer, further confirming the results of an interim analysis and justifying the novel therapy’s FDA approval. These updated results were first presented at the 2013 Annual Meeting of the American Society of Clinical Oncology and recently published in The New England Journal of Medicine.”
Metastasis is responsible for most cancer deaths, but the organs to which specific types of cancers migrate differ. Prostate cancers tend to metastasize to bone tissue, causing bone-related complications. The symptoms of bone metastases can be very painful and disruptive. Fortunately, some patients can benefit from therapies developed specifically to treat these complications. Continue reading…
“Skeletal-related events (SREs) negatively affect the quality of life of patients with cancer. Vascular endothelial growth factor receptor (VEGFR)-targeted therapy is effective against bone metastasis in animal models, but the clinical efficacy of anti-VEGFR inhibitors against bone metastases remains unclear. Therefore, we aimed to investigate the efficacy of chemotherapy with bevacizumab, an anti-VEGF antibody, against bone metastases.”
A new drug known as radium-223 has been granted priority review by the FDA as a potential treatment for patients with castration-resistant prostate cancer (CRPC) that has spread to the bone. In a recent clinical study, radium-223 improved overall survival from 11.2 to 14.0 months and delayed skeletal-related events by 5 months. The drug works by targeting tumor cells in bone while sparing healthy bone marrow cells and requires fewer treatments than standard radiation therapy.
A phase II clinical study evaluated the effect of 1 and 3 grams per day of pomegranate extract on prostate-specific antigen doubling time (PSADT) in men with recurrent prostate cancer. PSADT is the amount of time it takes for PSA levels to double. Both doses were associated with more than a 6-month increase in PSADT without any significant side effects.
Data from patients with prostate cancer and bone metastases was analyzed for patterns of healthcare utilization and cost of skeletal-related events (SREs). Events included spinal cord compression, fracture, surgery, and radiotherapy. Fifty-three percent of patients had at least one SRE and the most costly were events requiring inpatient surgery.
Researchers from the MD Anderson Cancer Center in Houston show that β1 integrin activation occurs in metastatic progression of prostate cancer and is constitutively active in late state prostate cancer cells. The study shows the integrin palys a reole in survival of metastatic prostate cancer cells in circulation. Inhibition of β1 integrin activity by antibody or knockdown results in increased apoptosis.
Nearly 2,800 men participated in the four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) observational clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7).